[
  {
    "ts": null,
    "headline": "PBH vs. ABT: Which Stock Should Value Investors Buy Now?",
    "summary": "PBH vs. ABT: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=aab4290e4822bea585047ee6390fe84b468536881c122dbcd231a59d8be9588c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765989603,
      "headline": "PBH vs. ABT: Which Stock Should Value Investors Buy Now?",
      "id": 137817054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "PBH vs. ABT: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=aab4290e4822bea585047ee6390fe84b468536881c122dbcd231a59d8be9588c"
    }
  },
  {
    "ts": null,
    "headline": "How The Abbott Takeover Is Rewriting Exact Sciences Story And Valuation",
    "summary": "Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as the discount rate edges up to 7.27 and long term revenue growth expectations tick higher to 12.44. These subtle shifts in the model reflect how the market is increasingly viewing the story through the lens of deal completion, while still acknowledging improving topline momentum in the core...",
    "url": "https://finnhub.io/api/news?id=94f7059eb2882d64a5b1799a7ae0b6a1b9679da4c5c9e485cd402c50dc9f6faf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765984235,
      "headline": "How The Abbott Takeover Is Rewriting Exact Sciences Story And Valuation",
      "id": 137817055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as the discount rate edges up to 7.27 and long term revenue growth expectations tick higher to 12.44. These subtle shifts in the model reflect how the market is increasingly viewing the story through the lens of deal completion, while still acknowledging improving topline momentum in the core...",
      "url": "https://finnhub.io/api/news?id=94f7059eb2882d64a5b1799a7ae0b6a1b9679da4c5c9e485cd402c50dc9f6faf"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Abbott Laboratories (ABT) a Buy Now?",
    "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=c9a763b3bdbfbe4e6d75dea03aba459b8c611fb0cd427d202eac4a089564a817",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765980003,
      "headline": "Is Trending Stock Abbott Laboratories (ABT) a Buy Now?",
      "id": 137817056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=c9a763b3bdbfbe4e6d75dea03aba459b8c611fb0cd427d202eac4a089564a817"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Shareholders Will Want The ROCE Trajectory To Continue",
    "summary": "What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...",
    "url": "https://finnhub.io/api/news?id=5e976131c9dba4f9f57fcb35d639fe22001d0444dfd5ee669b0a8764fd23fc15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765969215,
      "headline": "Abbott Laboratories (NYSE:ABT) Shareholders Will Want The ROCE Trajectory To Continue",
      "id": 137817057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...",
      "url": "https://finnhub.io/api/news?id=5e976131c9dba4f9f57fcb35d639fe22001d0444dfd5ee669b0a8764fd23fc15"
    }
  },
  {
    "ts": null,
    "headline": "Blood Glucose Monitor Market Set to Reach USD 25.4 Billion by 2030 with a CAGR of 9.1%",
    "summary": "The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing at a CAGR of 9.1%. This growth is fueled by the increasing prevalence of diabetes, a rising geriatric population, and enhanced self-monitoring awareness. Technological advancements in continuous glucose monitoring (CGM), smartphone integration, and AI data analytics have boosted accuracy and patient engagement. The self-monitoring blood glucose systems segment leads in mark",
    "url": "https://finnhub.io/api/news?id=f974c14d268e0ae66f86eda9a8135767ef28d6e00762600b2a0eaa1a9758762c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765962840,
      "headline": "Blood Glucose Monitor Market Set to Reach USD 25.4 Billion by 2030 with a CAGR of 9.1%",
      "id": 137817058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing at a CAGR of 9.1%. This growth is fueled by the increasing prevalence of diabetes, a rising geriatric population, and enhanced self-monitoring awareness. Technological advancements in continuous glucose monitoring (CGM), smartphone integration, and AI data analytics have boosted accuracy and patient engagement. The self-monitoring blood glucose systems segment leads in mark",
      "url": "https://finnhub.io/api/news?id=f974c14d268e0ae66f86eda9a8135767ef28d6e00762600b2a0eaa1a9758762c"
    }
  },
  {
    "ts": null,
    "headline": "Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors?",
    "summary": "Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the company’s Interventional Technologies segment through fiscal year 2027. At the same time, Riverwater Partners exited its Haemonetics position, reallocating capital to companies with clearer near-term catalysts even as it acknowledged Haemonetics’ essential role in hospital blood management and...",
    "url": "https://finnhub.io/api/news?id=59c3def66bd9dde8753df4688c13b48c96b2b24311da2252fc7ba8cdfa4fab0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765951598,
      "headline": "Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors?",
      "id": 137817059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the company’s Interventional Technologies segment through fiscal year 2027. At the same time, Riverwater Partners exited its Haemonetics position, reallocating capital to companies with clearer near-term catalysts even as it acknowledged Haemonetics’ essential role in hospital blood management and...",
      "url": "https://finnhub.io/api/news?id=59c3def66bd9dde8753df4688c13b48c96b2b24311da2252fc7ba8cdfa4fab0b"
    }
  },
  {
    "ts": null,
    "headline": "1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down",
    "summary": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.",
    "url": "https://finnhub.io/api/news?id=0c08cfded76852ba42ee09316516c14330f23157308e16f6fca94cdba8f82d20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765945939,
      "headline": "1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down",
      "id": 137817060,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.",
      "url": "https://finnhub.io/api/news?id=0c08cfded76852ba42ee09316516c14330f23157308e16f6fca94cdba8f82d20"
    }
  }
]